Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 885

Results For "ED"

9539 News Found

Granules gets ANDA approval for Dofetilide capsules
Drug Approval | October 18, 2021

Granules gets ANDA approval for Dofetilide capsules

The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Biotech | October 18, 2021

Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme


Govt. removes export curbs on Covid-19 kits
Policy | October 16, 2021

Govt. removes export curbs on Covid-19 kits

The export policy of all diagnostic kits and reagents (including instruments /apparatus) ... is being made free with immediate effect," the directorate general of foreign trade (DGFT) said in a notification


Metropolis Healthcare board approves acquisition of Hitech for Rs 636 crore
Clinical Trials | October 16, 2021

Metropolis Healthcare board approves acquisition of Hitech for Rs 636 crore

The revised deal involves a cash consideration only as against the earlier proposal of cash and equity


Exelixis in-licenses second anti-cancer compound from Aurigene
Biotech | October 15, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene

U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma


Expect normal quarter in Q2FY22: Emkay
News | October 15, 2021

Expect normal quarter in Q2FY22: Emkay

Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report


AUM Biosciences closes US $ 27 million `Series A’ funding round
Startup | October 15, 2021

AUM Biosciences closes US $ 27 million `Series A’ funding round

Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate


Govt launches `One Health’ surveillance programme
Public Health | October 15, 2021

Govt launches `One Health’ surveillance programme

The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens


Hospitals to accelerate digital investments: Frost & Sullivan
Digitisation | October 14, 2021

Hospitals to accelerate digital investments: Frost & Sullivan

The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions